Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
denikitug + nivolumab
- Development stage
- Phase 2
- Lead developer
- Gilead Sciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Denikitug + nivolumab is an investigational combination immunotherapy regimen consisting of denikitug (GS-1811), an afucosylated humanized monoclonal antibody targeting C-C chemokine receptor type 8 (CCR8), and nivolumab (Opdivo), an approved anti-programmed cell death protein 1 (PD-1) monoclonal antibody. Denikitug is designed to selectively deplete immunosuppressive regulatory T cells (Tregs) in the tumor microenvironment via antibody-dependent cellular cytotoxicity (ADCC). Nivolumab blocks the PD-1/PD-L1 checkpoint pathway to restore T-cell-mediated anti-tumor immune responses. Developed by Gilead Sciences, this combination is being evaluated in Phase 2 clinical trials for the treatment of advanced solid tumors, including HER2-negative, unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinomas, as well as advanced microsatellite-stable (MSS) colorectal cancer.
- Other names
- GS-1811 + nivolumabJTX-1811 + nivolumabdenikitug + Opdivo
02
Targets
CCL1CCR8PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on denikitug + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on denikitug + nivolumab.